Feedback / Questions
RNDO-564 - Rondo Therap
https://www.businesswire.com/news/home/20251203549891/en/Rondo-Therapeutics-Doses-First-Patient-in-Phase-1-Trial-of-RNDO-564-a-First-in-Class-Co-Stimulatory-Bispecific-Antibody-Targeting-Nectin-4-in-Advanced-Solid-Tumors
Dec 3, 2025
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Next